Polymer: bioceramic composites optimization by tetracycline addition.
The aim of this study was to evaluate the biocompatibility of composites of poly-lactic acid polymer (PLA) and copolymer of lactic and glycolic acid (PLGA), dispersed in a bioceramic matrix, Osteosynt (BC), to which tetracycline (TC) was added. The in vitro test used direct contact test (ASTM F-813) and elution test (USP-XXIII, ISO 10993-5), and in vivo evaluation was performed after subcutaneous implantation in outbread Swiss mice. The 0.01% (w/w) TC addition did not affect composite cytotoxicity in vitro. The macroscopic and histologic evaluation in vivo after 1, 7, 13, 21, 28 and 56 days showed an initial intense infiltrate of inflammatory cells for most of the groups. The tissue showed normal pattern after 21 days for all the groups. TC addition exhibited significantly larger reduction of inflammation signs (Mann-Whitney test, p<0.05) in the critical period of the resolution of the inflammatory process. Angiogenesis, cellular adsorption and fibrous deposit were observed on SEM evaluation. In conclusion, TC addition optimized composites polymer/bioceramic biocompatibility, contributing to anti-inflammatory response during the early phases of the wound healing process.
Pataro
André L
AL
Departamento de Odontologia Restauradora da Faculdade de Odontologia da Universidade Federal de Minas Gerais (UFMG), Brazil.
Oliveira
Michele F
MF
Teixeira
Karina I R
KI
Turchetti-Maia
Regina M M
RM
Lopes
Miriam T P
MT
Wykrota
Francisco H L
FH
Sinisterra
Rubén D
RD
Cortés
Maria E
ME
D000818:Animals; D018786:Bone Substitutes / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D002130:Calcium Phosphates / Q000737:chemistry; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002516:Ceramics / Q000737:chemistry* / Q000494:pharmacology; D017886:Durapatite / Q000737:chemistry; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D020007:Implants, Experimental; D007249:Inflammation / Q000473:pathology / Q000517:prevention & control; D019344:Lactic Acid / Q000737:chemistry / Q000494:pharmacology; D008297:Male; D008422:Materials Testing; D051379:Mice; D008855:Microscopy, Electron, Scanning; D011091:Polyesters; D011100:Polyglycolic Acid / Q000737:chemistry / Q000494:pharmacology; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry* / Q000494:pharmacology; D016062:Porosity; D040521:Subcutaneous Tissue / Q000187:drug effects / Q000473:pathology; D013499:Surface Properties; D013752:Tetracycline / Q000737:chemistry* / Q000494:pharmacology
D018786:Bone Substitutes; D002130:Calcium Phosphates; D011091:Polyesters; D011108:Polymers; C485817:beta-tricalcium phosphate; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C033616:poly(lactide); D017886:Durapatite; D013752:Tetracycline